Facebook
Twitter
LinkedIn
Forward
Updates in Lung Cancer Management
This one day symposium will raise and address challenging questions in current clinical practice for thoracic oncology. Topics include updates in perioperative therapy, treatment of KRAS mutated NSCLC, managing challenging immunotherapy toxicities, and the role of telemedicine in cancer care.
Target Audience
Physicians, physician assistants, nurse practitioners and allied health professionals
Learning Objectives
Participants who engage in this educational activity will be able to:
- Improve understanding of new systemic treatment options, including targeted therapy and immunotherapy for lung cancer
- Improve understanding of radiation options in lung cancer
- Improve understanding of surgical options in the treatment of lung cancer
7:30 – 8:00 a.m. Check-in / View Exhibits
8:30 – 9:10 a.m. Surgeon’s Perspective on the Management of NSCLC, Mario Gasparri, MD
9:00 – 9:40 a.m. Perioperative Therapy in NSCLC, Gregory Otterson MD, (James Thoracic Oncology Center)
9:40 – 10:10 a.m. Management of Centrally Located Tumors with Hypofractionated Radiation Regimens, Monica Shukla, MD
10:10 – 10:25 a.m. Break / View Exhibits
10:25 – 11:05 a.m. Management of KRAS Mutated Non-Small Cell Lung Cancer, Grace Dy, MD (Roswell Park Comprehensive Cancer Center)
11:05 – 11:45 a.m. Telemedicine for Cancer Care After the COVID-19 Pandemic , Howard West, MD (Access Hope)
11:45 - 11:55 a.m. Break/Lunch
11:55 a.m. – 12:25 p.m. Management of Immunotherapy Toxicities, Jonathan Thompson, MD
12:25 - 12:55 p.m. Therapeutic Advancements in the Management of Advanced Small Cell Lung Cancer, Huizi Chen, MD, PhD
12:55 p.m. Adjourn
Free parking is available for all attendees. Access to the surface lot via the gate on Jackson Street.
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
Guest Speakers:
| Name | Company | Role |
|---|---|---|
| Grace Dy, MD | Amgen, Eli Lilly, Mirati, Takeda, AstraZeneca | Consultant |
| Mario Gasparri, MD | Atricure, Intuitive Surgical | Consultant |
| Howard West, MD | ||
| Gregory Otterson, MD | BeiGene, AbbVie, Array Pharmaceuticals, AstraZeneca, BMS, Dizal, Elevation Oncology, Genentech, Pfizer, Revolution Medicine | Investigator |
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 4.0 hours of participation for continuing education for allied health professionals.
Available Credit
- 4.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 4.00 Hours of ParticipationHours of Participation credit.